Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Efsitora improves HbA1c control compared to degludec in Japanese adults.
Last updated July 17, 2026
Key finding
Mean HbA1c decreased from 8.04% to 6.63% with efsitora.
This study compared once-weekly efsitora to once-daily degludec in reducing HbA1c levels in Japanese adults with type 2 diabetes, finding comparable efficacy.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared once-weekly efsitora to once-daily degludec in reducing HbA1c levels in Japanese adults with type 2 diabetes, finding comparable efficacy.
Clinical relevance
This research is significant as it provides evidence that efsitora, a less frequent dosing option, can effectively manage blood sugar levels in individuals with type 2 diabetes. This may improve adherence to treatment regimens, potentially leading to better long-term health outcomes for patients. Understanding the effectiveness of efsitora compared to established treatments like degludec can help clinicians make informed decisions about diabetes management.
Keep in mind
Unclear effectiveness due to lack of statistical significance in some outcomes Limited generalizability to populations outside Japan Potential unmeasured confounders affecting results
Published in
Journal Reference
Publication details and source links for this paper.
Arihiro K, Mariko I, Yasushi T, Risa N, Hirotaka W. Once-weekly efsitora is comparable to once-daily degludec in reducing HbA1c in Japanese adults with T2D. Diabetes Therapy. 2026;17(5):771-785. doi:10.1007/s13300-026-01860-w
Main Effects
Efsitora reduced mean HbA1c from 8.04% to 6.63% (decrease of -1.41%)
Degludec reduced mean HbA1c from 8.00% to 6.64% (decrease of -1.36%)
Time in target glucose range was similar between efsitora and degludec
Rates of level 2/3 hypoglycemia were low for both treatments
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Efsitora, Insulin degludec and HbA1c, Severe hypoglycemia, Time in range.
This study contributes evidence to
Primary intervention
Efsitora
Primary outcomes
- HbA1c
- Severe hypoglycemia
- Time in range
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
5
Related topics
5
Evidence pairs
1421
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Insulin Therapies and HbA1c
Related evidence
Evidence relationship
Insulin Therapies and Hypoglycemia
Save evidence
Evidence topic
Hypoglycemia
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Efsitora and degludec both significantly lowered HbA1c levels by approximately 1.4%
- Time in target glucose range was comparable between both treatments
- Low incidence of severe hypoglycemia was reported for both medications
Who this applies to
- Japanese adults diagnosed with type 2 diabetes
- Patients requiring insulin therapy for blood sugar management
Keep in Mind
- Results may not be applicable to non-Japanese populations
- Further studies needed to confirm long-term safety and efficacy
- Study design limitations may affect the interpretation of effectiveness
Between the Lines
- Unclear effectiveness due to lack of statistical significance in some outcomes
- Limited generalizability to populations outside Japan
- Potential unmeasured confounders affecting results
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and HbA1c, Efsitora and HbA1c.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Insulin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceMedications
Efsitora → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
3 studies
outcome_hubMeasures HbA1c as a key outcome.
Insulin Therapies Evidence Hub
All studies on Insulin Therapies
3 studies
intervention_hubContributes to Insulin Therapies evidence base.
Efsitora Evidence Hub
All studies on Efsitora
2 studies
intervention_hubContributes to Efsitora evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Insulin degludec and HbA1c
Intervention: Insulin degludecOutcome: HbA1c
3 results
All studies on Efsitora and HbA1c
Intervention: EfsitoraOutcome: HbA1c
2 results
All studies on Insulin degludec
Intervention: Insulin degludec
3 results
All studies on Efsitora
Intervention: Efsitora
2 results
All studies measuring HbA1c
Outcome: HbA1c
3 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do Insulin Therapies lower HbA1c?
Strong Evidence
Insulin Therapies may lower HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 19 supporting studies with generally consistent results and a positive effect signal.
Do Insulin Therapies affect hypoglycemia?
Strong Evidence
Insulin Therapies may affect hypoglycemia.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Does Efsitora lower HbA1c?
Moderate Evidence
Efsitora appears to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Efsitora affect severe hypoglycemia?
Emerging Evidence
Current evidence does not show a clear effect of Efsitora on severe hypoglycemia.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Early insulin degludec improves DKA resolution timeHigher TI Dosing Needed for Effective Glucose ManagementIDegAsp may reduce nocturnal hypoglycemia compared to IGlar in T2DM patientsAHCL Improves Glycemic Control in Adults with Type 1 DiabetesAHCL system improves glycemic control in adults with T1DM
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.